Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (Nasdaq: SPPI) concerning possible violations of federal securities laws.

If you purchased shares of Spectrum and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

The investigation focuses on a statement by Spectrum that it failed to disclose that the Food & Drug Administration advised it to not submit a New Drug Application for its drug candidate apaziquone back in December of 2012.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Khang & Khang LLPJoon M. Khang, Esq.Telephone: 949-419-3834Facsimile: 949-225-4474joon@khanglaw.com

Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Spectrum Pharmaceuticals Charts.
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Spectrum Pharmaceuticals Charts.